Cerebral mechanism of celecoxib for treating knee pain: study protocol for a randomized controlled parallel trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 20; no. 1; p. 58
• Main Authors: Tang, Chenjian, Dong, Xiaohui, He, Wenhua, Cheng, Shirui, Chen, Yang, Huang, Yong, Yin, Bao, Sheng, Yu, Zhou, Jun, Wu, Xiaoli, Zeng, Fang, Li, Zhengjie, Liang, Fanrong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.01.2019; BioMed Central; BMC
• Subjects: Adult; Angiogenesis inhibitors; Anti-inflammatory agents; Arthralgia - diagnosis; Arthralgia - drug therapy; Arthralgia - physiopathology; Arthritis; Brain - diagnostic imaging; Brain - drug effects; Brain - physiopathology; Brain Mapping - methods; Brain research; Celecoxib; Celecoxib - adverse effects; Celecoxib - therapeutic use; Central mechanism; Central nervous system; Cerebrum; China; Chinese medicine; Chronic pain; Chronic Pain - diagnosis; Chronic Pain - drug therapy; Chronic Pain - physiopathology; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Depression (Mood disorder); Diagnostic imaging; Drug therapy; Female; fMRI; Health surveys; Humans; Informed consent; Knee; Knee osteoarthritis; Knee pain; Magnetic Resonance Imaging; Male; Medical imaging; Medical research; Middle Aged; Neuroimaging; Nonsteroidal anti-inflammatory agents; Nonsteroidal anti-inflammatory drugs; Osteoarthritis; Osteoarthritis, Knee - diagnosis; Osteoarthritis, Knee - drug therapy; Osteoarthritis, Knee - physiopathology; Pain management; Pain Measurement; Patients; Physiological aspects; R&D; Randomized Controlled Trials as Topic; Research & development; Study Protocol; Testing; Time Factors; Treatment Outcome; Tumor necrosis factor-TNF; Ulcers; China; fMRI; Knee osteoarthritis; Celecoxib; Central mechanism; Chronic pain
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-018-3111-8

Celecoxib is frequently prescribed to treat knee osteoarthritis (KOA), but how celecoxib influences the activity of the central nervous system to alleviate chronic pain remains unclear. One hundred eight patients with KOA will be enrolled in this study. Patients will be allocated randomly to three groups: the celecoxib group, the placebo group, and the waiting list group. The patients in the celecoxib group will orally take celecoxib 200 mg once daily and the patients in placebo group with placebo 200 mg every day for 2 weeks. Functional magnetic resonance imaging scan will be performed on all patients at baseline and the end of interventions to detect the cerebral activity changes. The short form of McGill pain questionnaire and the Visual Analog Scale will be used as the primary endpoints to evaluate the improvement of knee pain. The secondary endpoints include the Western Ontario and McMaster osteoarthritis index (WOMAC), the Attention Test Scale, the Pain Assessment of Sphygmomanometer, the Self-rating Anxiety Scale, the Self-rating Depression Scale, and 12-Item Short Form Health Survey (SF-12). The results will investigate the influence of celecoxib treatment on cerebral activity of patients with KOA and the possible relationship between the cerebral activity changes and improvement of clinical variables so as to explore the central mechanism of celecoxib in treating knee pain. ChiCTR-IOR-17012365 . Registered on August 14, 2017.